CA2303771A1 - Alleles du gene phospholipase c-.gamma.1 associe au trouble bipolaire - Google Patents
Alleles du gene phospholipase c-.gamma.1 associe au trouble bipolaire Download PDFInfo
- Publication number
- CA2303771A1 CA2303771A1 CA002303771A CA2303771A CA2303771A1 CA 2303771 A1 CA2303771 A1 CA 2303771A1 CA 002303771 A CA002303771 A CA 002303771A CA 2303771 A CA2303771 A CA 2303771A CA 2303771 A1 CA2303771 A1 CA 2303771A1
- Authority
- CA
- Canada
- Prior art keywords
- phospholipase
- gene
- gamma
- bipolar disorder
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000020925 Bipolar disease Diseases 0.000 title claims abstract description 56
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 102000015439 Phospholipases Human genes 0.000 title claims abstract description 28
- 108010064785 Phospholipases Proteins 0.000 title claims abstract description 28
- 241000527994 Cyclotella gamma Species 0.000 title claims abstract 13
- 101150084750 1 gene Proteins 0.000 title claims abstract 11
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims abstract description 49
- 229910052744 lithium Inorganic materials 0.000 claims abstract description 49
- 230000004044 response Effects 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 5
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 5
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 239000000523 sample Substances 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 230000008238 biochemical pathway Effects 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 238000003209 gene knockout Methods 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 210000001082 somatic cell Anatomy 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000011161 development Methods 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 238000004393 prognosis Methods 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 108700028369 Alleles Proteins 0.000 description 13
- 102000014384 Type C Phospholipases Human genes 0.000 description 10
- 108010079194 Type C Phospholipases Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 7
- 108010044467 Isoenzymes Proteins 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 238000011321 prophylaxis Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 5
- 150000003906 phosphoinositides Chemical class 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 108091092878 Microsatellite Proteins 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 101150001275 yl gene Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000008775 paternal effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 101150080509 Plcg1 gene Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000003297 denaturating effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 102000006029 inositol monophosphatase Human genes 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 230000009907 neuroendocrine response Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention porte sur l'utilisation du gène phospholipase C-.gamma.1 associé au diagnostic, au pronostic et au développement de traitements des troubles bipolaires et/ou de la réaction au lithium. L'invention porte également sur un procédé d'identification du patient susceptible d'être affecté par un trouble bipolaire et/ou réagissant au lithium, ce procédé consistant à: a) prélever sur le patient un échantillon d'acide nucléique; et b) déterminer les allèles du gène phospholipase C-.gamma.1 présent dans l'échantillon, certains allèles présentant un risque de trouble bipolaire et/ou de réaction au lithium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002303771A CA2303771A1 (fr) | 1997-09-24 | 1998-09-24 | Alleles du gene phospholipase c-.gamma.1 associe au trouble bipolaire |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2,216,686 | 1997-09-24 | ||
| CA 2216686 CA2216686A1 (fr) | 1997-09-24 | 1997-09-24 | Variants alleliques du gene de la phospholipase c-.gamma.1 associes aux troubles bipolaires |
| PCT/CA1998/000940 WO1999015697A1 (fr) | 1997-09-24 | 1998-09-24 | ALLELES DU GENE PHOSPHOLIPASE C-η1 ASSOCIE AU TROUBLE BIPOLAIRE |
| CA002303771A CA2303771A1 (fr) | 1997-09-24 | 1998-09-24 | Alleles du gene phospholipase c-.gamma.1 associe au trouble bipolaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2303771A1 true CA2303771A1 (fr) | 1999-04-01 |
Family
ID=25679654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002303771A Abandoned CA2303771A1 (fr) | 1997-09-24 | 1998-09-24 | Alleles du gene phospholipase c-.gamma.1 associe au trouble bipolaire |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2303771A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101666B2 (en) | 2001-08-31 | 2006-09-05 | Centre For Addiction And Mental Health | Involvement of the BDNF gene in mood disorders |
-
1998
- 1998-09-24 CA CA002303771A patent/CA2303771A1/fr not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101666B2 (en) | 2001-08-31 | 2006-09-05 | Centre For Addiction And Mental Health | Involvement of the BDNF gene in mood disorders |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Turecki et al. | Evidence for a role of phospholipase C-γ1 in the pathogenesis of bipolar disorder | |
| Bouchard | Genetics of obesity: what we have learned over decades of research | |
| Monsalve et al. | A missense mutation at codon 188 of the human lipoprotein lipase gene is a frequent cause of lipoprotein lipase deficiency in persons of different ancestries. | |
| Nomura et al. | Specific filaggrin mutations cause ichthyosis vulgaris and are significantly associated with atopic dermatitis in Japan | |
| US7943338B2 (en) | Autoimmune conditions and NADPH oxidase defects | |
| Azzedine et al. | Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma | |
| Dempster et al. | Evidence of an association between the vasopressin V1b receptor gene (AVPR1B) and childhood-onset mood disorders | |
| Ruano et al. | Association of the gene encoding neurogranin with schizophrenia in males | |
| Loos et al. | Association of lipin 1 gene polymorphisms with measures of energy and glucose metabolism | |
| US7488576B2 (en) | Methods for diagnosis and treatment of psychiatric disorders | |
| Giardina et al. | Characterization of the loricrin (LOR) gene as a positional candidate for the PSORS4 psoriasis susceptibility locus | |
| McCarthy et al. | The Alzheimer's associated 5′ region of the SORL1 gene cis regulates SORL1 transcripts expression | |
| Lemos et al. | The rs2292239 polymorphism in ERBB3 gene is associated with risk for type 1 diabetes mellitus in a Brazilian population | |
| Ftouhi‐Paquin et al. | Identification of three polymorphisms in the translated region of PLC‐γ1 and their investigation in lithium responsive bipolar disorder | |
| JP2002526124A (ja) | 変異型ｇｐｉｉｉａ対立遺伝子および／または変異型ｇｐｉｉｂ対立遺伝子の存在を決定することにより、神経系疾患のリスクを有する対象を治療又は同定する方法 | |
| WO1999015697A1 (fr) | ALLELES DU GENE PHOSPHOLIPASE C-η1 ASSOCIE AU TROUBLE BIPOLAIRE | |
| CA2303771A1 (fr) | Alleles du gene phospholipase c-.gamma.1 associe au trouble bipolaire | |
| Fon et al. | Adenylosuccinate lyase (ADSL) and infantile autism: Absence of previously reported point mutation | |
| Qu et al. | Associations of ATF4 gene polymorphisms with schizophrenia in male patients | |
| Ballester et al. | Association of genetic variants and expression levels of porcine FABP 4 and FABP 5 genes | |
| Molfetta et al. | Mutational screening in the LDLR gene among patients presenting familial hypercholesterolemia in the Southeast of Brazil | |
| Wang et al. | Case-control study of the UCH-L1 S18Y variant in sporadic Parkinson’s disease in the Chinese population | |
| D’Angelo et al. | Hypomethylation of the MEG8: Int2-DMR in patients with pathogenic PLAG1 variants suggests new role of the chr14q32 imprinting cluster in Silver-Russell syndrome | |
| Mahjoub et al. | Screening for Familial Hypercholesterolemia in Tunisia using Whole Exome Sequencing: Importance in diagnosis and healthcare management | |
| US20150031569A1 (en) | Mutations of the GPR179 Gene in Congenital Stationary Night Blindness |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |